Search research articles
Contact Us
Filters
Showing results (21-30 of 83) with videos related to
Page
of 9
Sort By:
Clinical Case Reports
|
December 20, 2018
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets
Michelle Ojemuyiwa, Karen Zeman, Alexander Spira, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 25, 2021
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Alexander Spira, Xiaolei Zhou, Lei Chen, et al.
Investigational New Drugs
|
April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Filip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
The Oncologist
|
March 9, 2023
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
Jun Zhang, Melissa Johnson, Minal Barve, et al.
Targeted Oncology
|
May 3, 2021
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
Alexander Spira, Aaron R Hansen, Wael A Harb, et al.
Investigational New Drugs
|
August 21, 2024
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Shubham Pant, Byoung Chul Cho, Christos E Kyriakopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
March 5, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial
Michael S Gordon, Richard D Carvajal, Alexander Spira, et al.
Frontiers in Oncology
|
September 23, 2021
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
Mark M Awad, Yvan Le Bruchec, Brian Lu, et al.
Frontiers in Oncology
|
June 24, 2022
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
Mark M Awad, Yvan Le Bruchec, Brian Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R Spigel, Craig Reynolds, David Waterhouse, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 83) with videos related to
Sort By:
Page
of 9
Clinical Case Reports
|
December 20, 2018
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets
Michelle Ojemuyiwa, Karen Zeman, Alexander Spira, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 25, 2021
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Alexander Spira, Xiaolei Zhou, Lei Chen, et al.
Investigational New Drugs
|
April 8, 2021
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Filip Janku, Patricia LoRusso, Aaron S Mansfield, et al.
The Oncologist
|
March 9, 2023
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
Jun Zhang, Melissa Johnson, Minal Barve, et al.
Targeted Oncology
|
May 3, 2021
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
Alexander Spira, Aaron R Hansen, Wael A Harb, et al.
Investigational New Drugs
|
August 21, 2024
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Shubham Pant, Byoung Chul Cho, Christos E Kyriakopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
March 5, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial
Michael S Gordon, Richard D Carvajal, Alexander Spira, et al.
Frontiers in Oncology
|
September 23, 2021
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
Mark M Awad, Yvan Le Bruchec, Brian Lu, et al.
Frontiers in Oncology
|
June 24, 2022
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
Mark M Awad, Yvan Le Bruchec, Brian Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R Spigel, Craig Reynolds, David Waterhouse, et al.
Page
of 9